TiGenix to present at the Jefferies 2017 Global Healthcare Conference in New York
(Thomson Reuters ONE) -
PRESS RELEASE
TiGenix to present at the Jefferies 2017 Global Healthcare Conference in New
York
Leuven (BELGIUM) - June 1, 2017, 07:00h CEST - TiGenix NV (Euronext Brussels and
NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the
anti-inflammatory properties of allogeneic, or donor-derived, stem cells to
develop novel therapies for serious medical conditions, today announces that
Eduardo Bravo, Chief Executive Officer, will be presenting at the Jefferies
2017 Healthcare Conference in New York on Wednesday, June 7 at 8:00 am EDT.
The TiGenix management team will be available for one-to-one meetings on
Wednesday, June 7 and Thursday, June 8. Please contact Investor Relations at
Investor(at)tigenix.com for a meeting request.
For more information
Claudia D'Augusta
Chief Financial Officer
T: +34 91 804 92 64
claudia.daugusta(at)tigenix.com
About TiGenix
TiGenix NV (Euronext Brussels and NASDAQ: TIG) is an advanced biopharmaceutical
company developing novel therapies for serious medical conditions by exploiting
the anti-inflammatory properties of allogeneic, or donor-derived, stem cells.
TiGenix lead product, Cx601, has successfully completed a European Phase III
clinical trial for the treatment of complex perianal fistulas - a severe,
debilitating complication of Crohn's disease. Cx601 has been filed for
regulatory approval in Europe and a global Phase III trial intended to support a
future U.S. Biologic License Application (BLA) is expected to start in 2017.
TiGenix has entered into a licensing agreement with Takeda, a global
pharmaceutical company active in gastroenterology, under which Takeda acquired
the exclusive right to develop and commercialize Cx601 for complex perianal
fistulas outside the U.S. TiGenix' second adipose-derived product, Cx611, is
undergoing a Phase I/II trial in severe sepsis - a major cause of mortality in
the developed world. Finally, AlloCSC-01, targeting acute ischemic heart
disease, has demonstrated positive results in a Phase I/II trial in acute
myocardial infarction (AMI). TiGenix is headquartered in Leuven (Belgium) and
has operations in Madrid (Spain). For more information, please visit
http://www.tigenix.com.
Forward-looking information
This press release may contain forward-looking statements and estimates with
respect to the anticipated future performance of TiGenix and the market in which
it operates. Certain of these statements, forecasts and estimates can be
recognised by the use of words such as, without limitation, "believes",
"anticipates", "expects", "intends", "plans", "seeks", "estimates", "may",
"will" and "continue" and similar expressions. They include all matters that are
not historical facts. Such statements, forecasts and estimates are based on
various assumptions and assessments of known and unknown risks, uncertainties
and other factors, which were deemed reasonable when made but may or may not
prove to be correct. Actual events are difficult to predict and may depend upon
factors that are beyond the Company's control. Therefore, actual results, the
financial condition, performance or achievements of TiGenix, or industry
results, may turn out to be materially different from any future results,
performance or achievements expressed or implied by such statements, forecasts
and estimates. Given these uncertainties, no representations are made as to the
accuracy or fairness of such forward-looking statements, forecasts and
estimates. Furthermore, forward-looking statements, forecasts and estimates only
speak as of the date of the publication of this press release. TiGenix disclaims
any obligation to update any such forward-looking statement, forecast or
estimates to reflect any change in the Company's expectations with regard
thereto, or any change in events, conditions or circumstances on which any such
statement, forecast or estimate is based, except to the extent required by
Belgian law.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: TiGenix via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 01.06.2017 - 07:00 Uhr
Sprache: Deutsch
News-ID 545636
Anzahl Zeichen: 5162
contact information:
Town:
Leuven
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 218 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"TiGenix to present at the Jefferies 2017 Global Healthcare Conference in New York"
steht unter der journalistisch-redaktionellen Verantwortung von
TiGenix (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
